![Han Hoon](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Han Hoon
Directeur/Membre du Conseil chez The Korean Society for Biomaterials
Postes actifs de Han Hoon
Sociétés | Poste | Début | Fin |
---|---|---|---|
AsiaCORD | Corporate Officer/Principal | 17/10/2011 | - |
Society for Hematology & Stem Cells | Corporate Officer/Principal | 17/10/2011 | - |
The Korean Society for Biomaterials | Directeur/Membre du Conseil | 17/10/2011 | - |
Historique de carrière de Han Hoon
Anciens postes connus de Han Hoon
Sociétés | Poste | Début | Fin |
---|---|---|---|
Stem Cell Therapy International, Inc.
![]() Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Président | 10/02/2010 | 23/02/2010 |
AmStem Corp.
![]() AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Président | 13/09/2010 | - |
Independent Dir/Board Member | 10/09/2010 | - | |
Hucord Co., Ltd.
![]() Hucord Co., Ltd. BiotechnologyHealth Technology Hucord Co., Ltd. is a biotechnology company engaged in human cell-based therapy. It develops stem cell technology along with the cord blood, specializing in Multi-Lineage Progenitor Cells (MLPCs) research, treatment of disease and banking of cells. The group works in the following divisions: cord blood banking, stem cell banking, stem cell research and development, stem cell therapy management and the immunogenetics laboratory. It also performs the Human leukocyte antigen typing method which determines the compatibility of tissues between patient and the donor. The company was founded on January 24, 1979 and is headquartered in Yongin-si, South Korea. | Directeur Général | 01/02/2000 | - |
Fondateur | 07/05/2010 | - |
Formation de Han Hoon
Catholic University of Korea | Doctorate Degree |
Statistiques
Internationale
Corée du Sud | 4 |
Etats-Unis | 4 |
Thaïlande | 2 |
Opérationnelle
Chairman | 2 |
Doctorate Degree | 2 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 3 |
Commercial Services | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
![]() | Health Technology |
Entreprise privées | 5 |
---|---|
Stem Cell Therapy International, Inc.
![]() Stem Cell Therapy International, Inc. Miscellaneous Commercial ServicesCommercial Services Stem Cell Therapy International, Inc. is a surgical procedure that has been used successfully for 70+ years as a treatment of many diseases for which modern medicine has had no therapy, or in which 'state-of-art' therapies stopped being effective. A documented 5 millions of patients have been so treated worldwide to-date, evidenced by over 120,000 publications in MEDLINE amongst others. SCT is approved for use by the German authorities and the EU. | Commercial Services |
AmStem Corp.
![]() AmStem Corp. Pharmaceuticals: OtherHealth Technology AmStem Corp. researches and develops stem cell transplantation therapy and regenerative medicine. The company owns cord blood stem cell bank in Korea. The company was founded on December 28, 1992 and is headquartered in San Francisco, CA. | Health Technology |
AsiaCORD | |
Society for Hematology & Stem Cells | |
The Korean Society for Biomaterials |